Thermo Fisher Scientific Expands Steriles Manufacturing and Research Capabilities in Asia-Pacific Region
The COVID-19 pandemic has demonstrated the feasibility of adapting clinical trials from site-based endeavors to fully decentralized or hybrid models and has increased global acceptance of decentralized trials as a safe and effective option for accelerating clinical research. Enabled by digital, technological, and logistical innovations, decentralized clinical trials offer advantages that will endure beyond the pandemic.
In this webinar, you will learn from our experts, Aruna Talapatra and Scott Emery, as they review the regulatory and geographic factors that can influence the adoption of DCTs, and it will provide a roadmap for implementing decentralized clinical trials within the current legal environment in Europe. Specifically, the presentation will address the critical importance of the following: